Table I.
Characteristics of the study population treated with guselkumab
| Characteristics | All patients (n = 264) | No previous biologics (n = 67) | 1 previous biologic (n = 114) | 2 or more previous biologics (n = 83) |
|---|---|---|---|---|
| Male, n (%) | 155/264 (58.7%) | 40/67 (59.7%) | 71/114 (62.3%) | 44/83 (53.0%) |
| Female, n (%) | 109/264 (41.3%) | 27/67 (40.3%) | 43/114 (37.7%) | 39/83 (47.0%) |
| Mean age, y ± SD | 50.3 ± 14.3 | 47.6 ± 15.1 | 49.3 ± 14.9 | 53.7 ± 12.3 |
| Mean PASI, score ± SD | 10.9 ± 8.5 (n = 128) | 16.7 ± 8.4 (n = 39) | 7.5 ± 7.4 (n = 55)∗ | 10.3 ± 7.1 (n = 34) |
| Mean PGA, score ± SD | 2.6 ± 0.9 | 3.1 ± 0.7 | 2.4 ± 1.0∗ | 2.6 ± 0.8∗ |
| Psoriatic arthritis, n (%) | 67/264 (25.4%) | 7/67 (10.4%) | 22/114 (19.3%) | 38/83 (45.8%) |
| Mean duration of psoriasis, y ± SD | 17.3 ± 11.7 | 11.2 ± 7.9 | 21.3 ± 12.1∗ | 21.5 ± 12.0∗ |
| Mean age at the first biologic, y ± SD | 45.2 ± 14.5 | 47.6 ± 15.1 | 44.6 ± 14.6 | 44.3 ± 12.6 |
| Number of previously failed biologic therapies, mean ± SD | 1.3 ± 1.2 | 0.0 ± 0.0 | 1.0 ± 1.0 | 2.9 ± 1.0 |
n, Number; PASI, psoriasis area severity index; PGA, physician global assessment; SD, standard deviation.
∗
P < .05 versus no previous biologic.